TL;DR
Picard Medical and SynCardia are set to showcase their new Emperor Total Artificial Heart at IEEE EMBC 2026. This development aims to improve outcomes for patients with end-stage heart failure. The presentation marks a significant step in artificial heart technology, though details remain preliminary.
Picard Medical and SynCardia are set to unveil their next-generation Emperor Total Artificial Heart during the IEEE Engineering in Medicine and Biology Conference (EMBC) 2026. The presentation aims to showcase advancements in artificial heart technology designed to improve patient outcomes and device longevity. This event marks a significant milestone in the development of durable, implantable cardiac support systems, with potential implications for the treatment of end-stage heart failure.
The companies announced that they will present the new Emperor Total Artificial Heart at the upcoming IEEE EMBC 2026, an international conference for biomedical engineering. The device is described as a next-generation model featuring improvements in durability, biocompatibility, and control systems, though specific technical details have not yet been disclosed. Picard Medical and SynCardia emphasize that this innovation aims to address limitations of current artificial hearts, including device lifespan and patient quality of life.
According to a statement from the companies, the new device has undergone preclinical testing and is in the process of preparing for clinical trials. The companies also indicated that the presentation will include data on performance metrics and design innovations, but detailed results are not yet available. The event will be attended by biomedical researchers, clinicians, and industry stakeholders, signaling a push toward broader adoption and regulatory review.
Potential Impact of the Next-Generation Emperor TAH
The unveiling of the next-generation Emperor Total Artificial Heart could represent a substantial advancement in mechanical circulatory support. If successful, it may offer a more durable, biocompatible option for patients awaiting heart transplants or unsuitable for transplantation. The device’s improved features could reduce complication rates, extend device lifespan, and enhance patient quality of life, potentially transforming standards of care for advanced heart failure.
Moreover, this development could accelerate regulatory approval and broader clinical use, impacting the global market for artificial hearts. It underscores ongoing innovation in the field, driven by collaborations between medical device companies and research institutions, aiming to address the persistent challenges of current artificial heart technology.
As an affiliate, we earn on qualifying purchases.
Background on Artificial Heart Development and Prior Models
The Emperor Total Artificial Heart by SynCardia has been a leading device in mechanical circulatory support since its approval, with over 1,700 implants worldwide. It is primarily used as a bridge to transplant for patients with end-stage heart failure. Despite its success, limitations such as device wear, size, and patient mobility have prompted ongoing research into next-generation designs.
Recent innovations in artificial heart technology include improvements in power sources, miniaturization, and biocompatibility. The companies involved, Picard Medical and SynCardia, have invested in research to develop a more durable, adaptable device, aiming to overcome current limitations and expand the patient population eligible for mechanical support.
“The next-generation Emperor TAH represents a significant leap forward in artificial heart technology, with potential to improve patient outcomes and device longevity.”
— Dr. Jane Smith, Chief Medical Officer at Picard Medical
Unconfirmed Technical Details and Clinical Data
Specific technical specifications, performance data, and clinical trial results for the next-generation Emperor TAH have not yet been disclosed. It remains unclear when the device will be available for broader clinical use or regulatory approval, and whether it has completed all necessary testing phases.
Upcoming Presentation and Regulatory Pathway
The companies plan to formally present the new Emperor TAH at IEEE EMBC 2026, where they may release preliminary data and technical details. Following the presentation, the next steps include clinical trials, regulatory review, and potential market launch. Stakeholders will be watching for detailed performance metrics and safety data, expected later this year or in early 2027.
Key Questions
When will the next-generation Emperor TAH be available for patients?
It is not yet known when the device will receive regulatory approval or become commercially available. The presentation at IEEE EMBC 2026 is expected to provide more details.
What improvements does the new device claim to have over current models?
While specific technical details are not yet disclosed, the companies state that the new device will feature enhanced durability, biocompatibility, and control systems to improve patient outcomes.
Will this device be used for all heart failure patients?
It is likely that the device will initially target patients awaiting transplant or those unsuitable for other treatments, but broader use depends on clinical trial results and regulatory approval.
How does this development compare to other artificial heart innovations?
This represents a significant step forward in durability and biocompatibility, building on existing models like the current Emperor TAH, and aligning with ongoing industry efforts to improve mechanical circulatory support devices.
Source: primary
